Bill's Feed
Apr 29, 2013

Express Scripts profit tops Wall St view, ups forecast

April 29 (Reuters) – Express Scripts Holding Co on
Monday reported higher-than-expected first-quarter earnings,
helped by greater use of more profitable generic medicines, and
the pharmacy benefit manager raised its full-year forecast.

Express said it expects improvements in gross profit over the
remainder of the year and now sees full-year adjusted earnings
of $4.23 to $4.33 per share, up from its prior outlook of $4.20
to $4.30 per share. Its shares rose 1.5 percent in after-hours
trade.

Apr 25, 2013

PerkinElmer profit misses expectations, lowers forecast

April 25 (Reuters) – PerkinElmer Inc on Thursday
reported lower-than-expected first-quarter profit and decreased
its full-year forecast as difficult economic conditions and a
stronger dollar hurt sales in Europe and Japan.

Investors used to PerkinElmer beating earnings expectations
and incrementally raising forecasts over the course of the year
punished the stock, sending it down 13 percent.

Apr 25, 2013

Biogen profit beats estimates, raises 2013 forecast

By Bill Berkrot

(Reuters) – Biogen Idec Inc (BIIB.O: Quote, Profile, Research, Stock Buzz) reported higher-than-expected first quarter profit on Thursday and raised its full year forecasts, and the U.S. biotechnology said it sees its new drug Tecfidera becoming the leading oral medicine for multiple sclerosis.

Biogen management declined to give any sales details from Tecfidera’s first few weeks on the market, but Chief Executive George Scangos called the March 27 U.S. approval “a watershed event for our company.”

Apr 24, 2013

Thermo Fisher profit tops Street view as Life awaits

April 24 (Reuters) – Laboratory equipment maker Thermo
Fisher Scientific Inc, which this month agreed to
acquire Life Technologies Inc for more than $13
billion, on Wednesday reported a higher-than-expected
first-quarter profit, helped by a 10 percent rise in specialty
diagnostics sales.

Excluding one-time items, Thermo Fisher posted earnings of
$1.37 per share, topping analysts average expectations by 8
cents, according to Thomson Reuters I/B/E/S.

Apr 23, 2013

Amgen first quarter sales disappoint, shares fall

April 23 (Reuters) – Amgen Inc on Tuesday reported
first-quarter sales that fell short of Wall Street expectations
for most of its biggest-selling medicines, and its shares fell
more than 6 percent.

Revenue for the quarter rose 5 percent to $4.24 billion, but
was shy of Wall Street expectations of $4.37 billion.

Apr 23, 2013

AbbVie hepatitis C drugs knock out virus at eight weeks

By Ransdell Pierson and Bill Berkrot

(Reuters) – A combination of five oral drugs being tested by AbbVie Inc cured at least 88 percent of new patients with hepatitis C after only eight weeks of treatment, without raising significant safety issues, researchers said on Tuesday.

The latest findings from an ongoing trial sponsored by AbbVie, called Aviator, also showed that 96 percent of patients taking the five medicines for 12 weeks eliminated the virus, as assessed by blood tests 24 weeks after they stopped treatment.

Apr 23, 2013

Bristol-Myers oral hepatitis C regimen looks competitive: study

By Bill Berkrot

(Reuters) – A combination of three experimental Bristol-Myers Squibb hepatitis C drugs appeared to be highly effective, according to data from a mid-stage clinical trial, keeping the company in the race for developing an all-oral treatment regimen for the serious liver disease.

The combination therapy, which involves three direct acting antiviral drugs that each attack different targets needed for replication of the hepatitis virus, achieved cure rates as high as 94 percent when given for either 12 weeks or 24 weeks, according to results of the small study.

Apr 22, 2013

Analysis: Ahead of reform, medical care slowdown hits companies

NEW YORK (Reuters) – As the clock ticks down to the start of a U.S. healthcare overhaul, companies from device makers to hospital chains have been surprised to see Americans make even fewer trips to the doctor’s office.

Use of non-emergency medical services has been weak for several years in the wake of a deep recession, high joblessness and the steadily rising cost of care.

Apr 22, 2013

Analysis – Ahead of reform, medical care slowdown hits U.S. companies

NEW YORK (Reuters) – As the clock ticks down to the start of a U.S. healthcare overhaul, companies from device makers to hospital chains have been surprised to see Americans make even fewer trips to the doctor’s office.

Use of non-emergency medical services has been weak for several years in the wake of a deep recession, high joblessness and the steadily rising cost of care.

Apr 22, 2013

Ahead of reform, medical care slowdown hits US companies

NEW YORK, April 22 (Reuters) – As the clock ticks down to
the start of a U.S. healthcare overhaul, companies from device
makers to hospital chains have been surprised to see Americans
make even fewer trips to the doctor’s office.

Use of non-emergency medical services has been weak for
several years in the wake of a deep recession, high joblessness
and the steadily rising cost of care.

    • About Bill

      "Based in New York, I primarily cover the pharmaceutical and biotechnology sectors as well as other publicly traded companies involved in health care. Previously covered a wide range of sports for Reuters."
    • Follow Bill